tv White House Monkeypox Response Team Holds Briefing CSPAN August 26, 2022 6:26pm-7:01pm EDT
happening in washington each day. subscribe using the qr code or visit the website to subscribe any time. the white house monkeypox response team gives an update on the response effort. the team discussed the vaccination rate increase and decline of cases across the nation. and deputy white house monkeypox response pointer will
provide an update on our partnership with impacted committees. . from the start, our vaccination strategy has been centered on reaching 1.6 million americans, including >> deputy white house monkeypox response coordinator dr dmitry daskalakis will provide an update on our partnership with impacted communities from the start. our vaccination strategy has been centered around reaching approximately 1.6 million americans including gay, bisexual and other men who have with men and others with a known high risk exposure to monkey box. to do that. we've worked nonstop to scale up access to the generous vaccine in the u. s. in fact, we have made more generous vaccine available than any other country in the world and because of the fda authorization of safe and effective intradermal vaccination, we can accelerate the number of shots in arms with the urgency. this outbreak warrants. as of this past monday, we have made 1.1 million vials of vaccine available jurisdictions that is the same total number of vials that
jurisdictions were expecting before fda approval of intradermal administration as administrator o'connell will discuss shortly. we're approaching having enough vaccine for everyone in the at risk community to receive two doses of vaccine. i'm also glad that we've seen significant progress in intradermal administration of vaccine in just the last two weeks. as of today, 75% of jurisdictions are already applying intradermal administration of vaccine and another 20% are working to move in that direction. this is important. progress in a short period of time as the community, as aulative 1.1 million vials are delivered to jurisdictions and as we get more supply, we are approaching the point where we can offer two doses of vaccine to the entire high risk population via intradermal administration. why we continue to deliver as much vaccine to states and jurisdictions as possible. our focus has to be
getting those shots into arms over the past couple of weeks. cdc has been working closely with jurisdictions and clinicians directly to operationalize the intradermal approach. they've hosted webinars with thousands of providers providing video trainings and our team is in touch with health leaders around the clock. as don will discuss in detail, we have made clear to jurisdictions, we stand ready to help in any way we can including providing additional vaccines. once a jurisdiction is attested to using more than 85% of their vials. currently, there are a handful of jurisdictions, approximately 1/5 that have attested to using 85% of their current supply. so our focus right now is working closely with clinicians and local health departments to get shots into arms. and importantly, we continue to encourage jurisdictions to focus vaccination efforts on getting vaccines out equitably to individuals at highest risk of contracting the virus. that's
why we are working closely with places like atlanta and new orleans to prepare for events like black pride and southern decadence and last week we got hundreds of vaccines out to individuals who participated in pride activities in charlotte north carolina. the bottom line is this. over the past three months we have made significant strides in increasing supply of vaccine, accelerating its delivery and strengthening our preparedness for the future. we have a robust supply of vaccine available for jurisdictions out in the field and we are working hand in hand with jurisdictions to get shots into arms to help adapt the intradermal approach and to answer their questions. we will also continue to everything in our power to address needs on the ground and adapt our response as needed so we can get this outbreak under control before i turned over to assistant secretary of connell. i want to take a moment to
recognize the work of jurisdictions. they're leveling up their operations to get more vaccines and arms. just this week, our team heard from health leaders here in d. c. who told us they were getting 900 shots out per day using the intradermal method and getting between 4.5 and five doses on average per vial. those aren't just numbers. that's real action impacting hundreds of people every day. so thank you to all the clinicians, health partners and members of the community for working together to combat this outbreak with that. let me turn over to assistant secretary o'connell. >> thanks so much and as we continue to do everything we can to increase the availability and accelerate the distribution of vaccines and treatments nationwide. with the goal of first offering vaccines to americans at high at highest risk of contracting monkey pox. as bob mentioned, we are soon
approaching the point where most people at highest risk will have access to two doses of genius. our work is far from over, but this is a step in the right direction as we continue to fight the spread of the virus. now, i'm happy to walk through the numbers to date across all four phases of the national vaccine strategy, we have allocated approximately 1.1 million vials of genius vaccine. we shipped about half of that number. prior to the fda issuing their emergency use authorization virginia's allowing for intradermal administration. so those 1st 600,000 or so vials were distributed when one vial equaled one dose. since the fda issued the e. u. a. on august 9th, we have shipped approximately 188,000 additional vials of vaccine, which represents up to 940,000 doses using the intradermal vaccination method covered by the eu a combined that comes to
about 1.5 million doses already distributed and in the field. now on monday we launched the fourth phase of our national vaccine strategy, making the next 360,000 vials of vaccine available to states and jurisdictions for ordering and distribution. using the intradermal administration method. jurisdictions can administer up to 1.8 million doses of vaccines from these files taken together by the end of phase four, we will have provided enough files to states and jurisdictions to provide more than three million doses of vaccines, meaning we have supplied nearly enough vaccine to reach the entire at risk population. we've got more to do but this is an important step along the way. now as supply continues to increase steadily and we ship out thousands of doses daily. it's important that we make sure vaccines are going to the people in places that need the most and that shots like bob said are getting into arms, not sitting on shelves as
part of phase four. in order for jurisdiction to order from its allocation, it must attest that it has utilized at least 85% of its current supply since monday 14 jurisdictions have attested to 85% utilization. and as soon as the jurisdiction let us know that they have used 85% of their supply, they can order more. the strategic national stockpile team, immediately fulfill those orders and ship them out of the jurisdictions that have attested to this 85% utilization since monday asper has shipped nearly 48,000 vials of vaccine which represents up to 240,000 doses. looking ahead, we anticipate another 150,000 vials of vaccine from our supplier, which represents up to 750,000 doses in all coming in as early as late september. in addition last week we announced that bavarian nordic reached an agreement with grand river aseptic manufacturing to establish the
first us based fill and finish virginia's in grand rapids michigan once up and running this facility will fill and finish 2.5 million vials we ordered this summer. this is an important step in building our domestic capacity and in providing domestic jobs in addition to getting vaccines out to those that need them most is also important to us that p pox is easily accessible for treatment to those at high risk for severe disease. that is why last week we announced that we would preposition up to 50,000 patients courses. that's three times as many treatment courses as there are monkeypox cases, jurisdictions are able to start ordering those treatment courses earlier this week and so far the sns has shipped out about 10,000 courses to 19 jurisdictions. that's in addition to the more than 22,000 courses we've already shipped. this approach allows us to preposition these treatment courses for quick and
easy access for patients who qualify for them. so bottom line, our message to states and jurisdictions is if you need vaccines if you need treatment or if you need additional support for your local response, please let us know and with that it's my pleasure to turn the program over to dr wilensky, >> thank you, administer o'connell. good afternoon everyone today. i'd like to share with you the latest information and data out of our local health departments and c. d. c. on the current monkeypox outbreak. as of august 25 over 46,700 cases have been detected globally in 98 countries. in the united states there have been nearly 17,000 cases of monkeypox identified across all 50 states, the district of columbia and puerto rico. throughout the current monkeypox outbreak, cdc has worked diligently to make data available as quickly as possible to help raise awareness and guide decision making. earlier this week, cdc posted updated data on our website providing an in depth look at monkeypox case, demographics and
symptoms, the use of tea packs and experimental treatment for monkeypox as well as data from a behavioral survey of gay and bisexual men. the posting of these data on our website prior to its publication in a scientific journal, is an example of the way we are working to modernize c. d. c. and share timely and actionable data with all of you today. cdc is posting additional data that provide a picture of monkey pox vaccine administration in the united states. our plan is to update these data on a weekly basis on the cdc website. it's important to note that the data we're releasing today reflect only 19 jurisdictions where data are flowing to c. d. c. forysis but the data do provide us with an insight and understanding of where we are in our efforts to administer vaccine to those at risk were actively collaborating with the remaining jurisdictions so that they can upload their data in response to our data use agreements. now i'd like to walk you through the vaccine administration data. cdc is releasing today data as of
august 23 show that over 207,000 doses of vaccine have been administered in these 19 jurisdictions. the data demonstrate that the vast majority of doses administered nearly 97%. our first doses with consistent week over week increases in vaccinations. while we are encouraged by the scale up, there are many people eligible for second doses and very few of the doses administered so far are recorded as second doses. i'd like to take this moment to emphasize that this is a two dose vaccine and it's important to receive the second dose in the series. i encourage providers to continue to highlight the importance of the second dose so that all vaccinated people optimize their protection from the vaccine. now, the administration data also show that among the first doses given the majority of recipients have been adults aged 25-39 with around 53% of first doses administered in this age
group. so far, the majority of first dose recipients, 92% have been males and 6% of doses have been administered to women. regrettably. we at cdc are not receiving data by gender and are unable to report it as such. those who are white represent about 47% of administered vaccines. those who are hispanic represent about 22% and those who are black represent about 10%. recently we've seen a demographic shift in new cases as black and hispanic men have increasingly and disproportionately represented new cases which further highlights the importance of equity and vaccine administration. given the early evidence of racial and ethnic disparities in monkey pox vaccine administration, cdc remains committed to reducing the impact of health disparities by collaborating with jurisdictions on provision of educational materials and promotion of equitable access to monkey pox vaccines were also working with communities to provide vaccine and harm reduction education at large
events attended by groups at highest risk for monkeypox right now. states, territories and large local jurisdictions in the united states have stepped up in the face of this outbreak and agreed to report secure protected data about monkey pox vaccine administration in their jurisdictions to the cdc. these data are essential to help us understand who the vaccines are going to and critically to make sure vaccines are getting to the communities where they are most needed. the data presented today are from 19 jurisdictions and as i previously mentioned, we're actively working with the remaining jurisdictions to get these data flowing. i want to emphasize that public health data in the united states are unique. they come from a complex decentralized landscape of state and local health departments with many points of friction that can keep data from coming from local jurisdictions to the c. d. c. the effort to secure monkey pox vaccine data represents how we at cdc are working hand in glove with our state and local partners and other federal agencies to continually improve our
approaches. our goal is swift, transparent, publicly available and actionable data and we will share additional jurisdictional data as they become available. finally, as students return to college campuses, i want to highlight that. earlier this week, cdc made information and resources readily available on our website about monkeypox for administrators, staff and students at colleges and universities. we will continue to provide the necessary nation and education and conduct outreach to those at risk. as you have heard me say many times before we remain open to feedback on how and where we can provide tailored information to those at highest risk. thank you and i'll now things turn things over to dr daskalakis. >> thank you so much. dr walensky today i wanted to provide an update on a key element of our response that's working closely with gay bisexual and other men who have with men to provide evidence based behavioral advice to help reduce the risk of monkeypox as we work to get vaccination and testing to scale. it has been a
top priority since the earliest days of the outbreak to communicate in plain and direct language about how monkeypox is transmitted and what actions people specifically, men who have with men can take to avoid exposure to this virus. it has been courting my and our mission to provide this advice in a way that reaches men who have with men in places they know and trust and to speak plainly and directly about behaviors associated with monkeypox transmission so that they and transgender and gender diverse individuals have the tools to navigate this outbreak. the queer community has been central in developing adapting and amplifying these messages as the outbreak has unfolded and the epidemiology further informed our advice to prevent monkeypox, 94% of cases were associated with sexual activity and nearly all the cases have been seen in gay, bisexual and other men who have with men today the cdc mmwr reports on a special monkey pox survey of participants of the american men's internet survey
or amos that both reinforced this strategy and highlights the important self motivated behavioral actions taken by m. s. m. during this outbreak to reduce their personal risk of infection and therefore the spread of monkeypox in the community, around 50% of surveyed men report having reduced their number of partners, reduced their one time sexual encounters and avoided some virtual and real space is associated with increased monkeypox exposure risk. a second mmwr describes a mathematical model that shows that temporary changes in behavior like the ones reported in the famous study would not only lead to a reduction in the percentage of people who got monkey pots but would also slow spread in the population, allowing more time for vaccination efforts to reach people who could benefit most. what this means is that the l g b t q ai plus people are doing things that are actually
reducing their risk and it's working and it speaks to the resilience and commitment of this community to addressing the challenge of monkeypox using every tool in their toolkit as well as the need for clear frank and community responsive advice from the partnership of public health and community. this is strong progress. it shows that the work we're doing to engage the community is having results and that the community has mobilized to protect itself. so let me be clear. the advice about how to reduce risk for monkeypox exposure is for now, not forever and is an important part of our public health and community response as we urgently surge vaccinations to control this outbreak. i'll hand the mic back to kevin for questions. >> get into a few questions. please keep your questions to one question. let's go to carla johnson of the associated press >> really about what you're doing to address the disparities. we're seeing in
these new numbers about vaccine administration particularly to the black and hispanic community. thanks >> i'm sorry, i'm happy to take that carl, thank you for that question. and let me just say that we anticipated that these numbers might come. we didn't wait for these numbers to take action. we are seeing the effects of disparities and we're taking action right away. one of the things i do want to say is part of the motivation for the pilot projects that that bob mentioned early on in charlotte as well as the black gay pride events that will be happening this labor day weekend is exactly to address these health disparities and inequities in vaccine administration. and we've seen as we're starting to roll these pilot projects out that they are working but not just in vaccination, but also in community and education as dimitri, just dr daskalakis just
noted. >> thanks. let me just see if dr daskalakis wants to add anything today. >> i'll just add really to what dr walensky said that really, you know, with with supply of vaccine increasing, i think we have a new opportunity in strategy which is bringing vaccine to people as opposed to trying to have people find vaccine. and so i think that the example of the events that we're talking about our but we have others, including allocations of vaccines that are going to ryan white clinics and federally qualified health centers and then also hearing on the ground since public health is a local event strategies that individual jurisdictions are using to actually get vaccines to smaller organizations that reach people better. thank you, >> kevin, next question. >> let's go to penn wang at npr >> hi, thanks for taking my question, i had a question about the epidemiology of the outbreak. so in new york and a few other cities, we're seeing some early signs that monkeypox cases might be starting to fall.
so i was wondering from your perspective if you think this is a real signal, could it be a turning point? and what does it mean about how to move forward? >> that's a great question. so, we have started to see globally that we may be turning a corner. we in the united states had our first case about two weeks after some of the european countries that we've also started to see turn around and as you note or turned downward, as you note, there are certain jurisdictions chicago san francisco, that are starting for report that they're starting to see a downward trend. i want to be cautiously optimistic about these. not only because of the downward trend, but because of the amos data that dr daskalakis just noted that we're actually seeing vaccine get out behaviors change harm reduction message is being heard and implemented and all of that working together to bend the curve, if you will. that said, i also want to say that week, over week, our numbers are still increasing the rate of rise is lower, but we are still seeing increases and we are of
course, a very diverse country and things are not even across the country. so we're watching this with cautious optimism and really hopeful that many of our harm reduction messages and our vaccines are getting out there and working. >> thanks kevin. can we go to another question, >> liz heilemann at paws? >> yes. i'm wondering if you could say more about the cases. i know there's not many of them yet among women but are those largely being largely related to sexual activity at this point or household transmission or what >> go back to dr wilensky? >> yeah. you know, there there there are very few of these. but what i will say is we generally doing epidemiologic investigations and for the most part we are finding that they all have some epidemiologic link to either a known case or a known exposure. so, we're following those very carefully.
and one by one really. and in terms of epidemiologic links, >> let's go to madison mueller at bloomberg. >> hi, yeah, i was wondering if you could say a bit more about the second shots and people not coming back for second shots. is that because people are choosing not to come back. is that because states, you know, until now didn't have the have enough supply to administer those second shots. i was just wondering if you could provide more detail there. >> dr wilensky. do you want to take that one. >> yeah, i can start and say we're just getting our first window into vaccine administration in general. and and the second shots, we have some jurisdictions that have been more vigorous in terms of getting those second shots out. as you probably recall, some of our jurisdictions were using delayed second shots as a dose sparing mechanism. we've been courage now that there are plenty of doses out there as administer o'connell noted that that is no longer necessary. and so we're anticipating that people will come back for the
second shot. so more to come on that. but i think one of the benefits now of having ample vaccine out there is that we have ample opportunity to administer, not just for our shots, but also these second shots. >> thank you, kevin. next question, >> let's go to jacqueline howard at cnn >> thanks for taking my question. we understand that in charlotte north carolina, when there were vaccination efforts at the pride festival there, we understand that about 540 doses of the 2000 doses were allocated. so looking forward are their plan in other locations like in atlanta, new orleans and others to make an effort to administer more of the allocated doses during large events. and what are those plans to ensure that more doses are used during these efforts at the
large events and during this type of outreach. >> yeah, we're definitely looking at events that expand our ability to through equity reach. not only at risk populations but focus on certain demographics. and through some of those events i mentioned the events in atlanta southern decadence down in new orleans. let me go ahead and ask dr daskalakis to add some other events that we're working on along with c. d. c. to bring additional vaccine. and more importantly public education outreach to. >> sure i'll start and then i'll hand it off to dr walensky as well. just to say that this is one of the reasons that this is a pilot to actually, you know, make sure that we're doing it on the ground in a way that makes great sense. and i also like to say, as i said before that really public health is a local experience and we're really providing and i think dr walensky can speak more, a lot of technical assistance. and then the local jurisdiction is actually optimizing how they're
delivering because they actually know there are people really well and know their organizations as well as their events. so i think, you know, as we go further with more events and we're getting hearing more and more events that are coming through jurisdictions, you know, it's going to get more and more fine tuned, which is again one of the reasons that this is such a great pilot >> yeah, maybe i'll just turn it back and say, you know, we got because of this pilot, we got 540 people who are otherwise potentially not have been vaccinated, vaccinated? probably reaching a very diverse community. and so i i would consider that a win again, we have more to learn but also to say that, you know, the vaccine adminis just one marker of the impact that we had in that at that event and the education um and information that we were able to share that event i think should not be overlooked. so i think we had what i would call a pretty successful first pilot and looking forward to lessons learned from that pilot and how we can expand and extend in
future future events. >> all right, let's go to julie at reuters. >> hey, can you hear me? thanks for taking my coat. so i have. the question i have is you know, basically on this comment that you had some providers reporting that on the intradermal vaccine, they were getting 4.5 to 5 doses per vial. i've actually heard from several sources that they're getting 3 to 4 doses per vial, including the washington state briefing just yesterday where they said exactly that they're doing 3 to 4 doses and some people are saying one of the issues is that they don't have the proper syringes that would allow them to get those if you're finding that not actually getting five doses provided? would would you consider that happening. and would you consider readjusting your estimates on the number of doses that will be available? thank you.
>> yeah. so let me start with dr wilensky and then we'll go to dr daskalakis. >> yeah, great, thank you for that question. so we have said that these vials may contain up to five doses. i do want to be clear that we recognize that not all vials will will providers be able to get five doses out of as you know three? maybe some possibility. we also recognize that in some situations they may be only able to use a single dose from that vile either because um it's administered to a child or to somebody who has um a kilo reaction from sub q dozing. so we have built in a buffer as we've been allocating and distributing to rest assured that people who are getting the doses that they need without anticipating that every single one is going to get five doses of the vial. >> and i'll just add that the feedback is actually always very important. and we're really trying to shift the thinking away from how many vaccines can you pull out of the vial? but how many arms can you vaccinate? because that's gonna give us a
lot more information. and so getting the information from jurisdictions some of the administration data you're seeing for the first time online today, that data is going to be really helpful for us to understand what's happening on the ground? so with studies having been done that up to five could be drawn out of the vials. it's important to know what's happening in the real world. and i'll also add and i think maybe i'll send it back to bob as well or to don that in terms of the vials compared two doses, jurisdictions are experiencing a higher number of vaccines that they are able to give an arms based on the number of vials that they've gotten as well. so regardless of how many they pulled because of that buffer, it's still in that increase in doses, i'm not sure if bob or don't want to comment to, >> if i can just add one more piece to this. you know, the most important thing to us is getting these vaccines out and into arms as dimitri just mentioned if the state comes to us and says they've used 85% of their supplies, they are able to order the next bit. we are not in the business of holding vaccines back. if people need them, if if jurisdictions are using them, if they're getting
out whether it's 345 per vial, if they've used 85% of what we've given them there, they can come back and get more and that's really important to us that we continue to move these vaccines to those that need the most. >> yeah, i think that's the key part is the vaccines available, we want to administer as much vaccine as we can to the to reach the most at risk population. um while we want to optimize each vial of vaccine and and as i said in my opening talk to washington d. c. this week and they were getting 4.5 to 5, i talked to a number of other jurisdictions for those that are having difficulty. we're working with them and providing resources to help them optimize that. but the key is many more doses are available now than would have been available and we're reaching much more of that risk population. let's go back to kevin for another question. >> you cut out if you could
restart your question, >> can you hear me now? right. so with the intradermal approach, we've heard from some local officials who say that this technique may be more painful or uncomfortable and it can scar. are you guys at all concerned that this may dissuade people from getting the vaccine? and if so, how do you plan to address that with your messaging? >> yeah. so let me start off with dr daskalakis who's actually administered the inter drama approach and talk about and then let me go to dr wilensky and see if she wants to add anything. >> so i'll start by saying, i'm looking at the studies. um, the intradermal route actually may have more redness and itching but tends to have less pain in terms of the scarring issue. um i think specifically individuals who have a history of keloid, that's something that's very specifically concerning, but less concerning among others. so i think what we're, what we're doing is making sure that
jurisdictions are armed with right information is as well as other trusted messengers to make sure that they get the word out. and i think that the desire for protection here, i think is going to be important to overwhelm some of the concern for the local reactions which when when compared to the subcutaneous is fairly equivalent. dr walensky? >> well, thank you. this includes our program today. have a great weekend tonight. >> watch the senate hearing at 8 p.m. on c-span. >> c-span brings you an unfiltered view of government. our newsletter recaps the day for you. scan the qr code to sign up for
this and stay up-to-date on anything -- everything happening in washington. visit c-span.org to subscribe anytime. over the past 21 years in partnership with the library of congress, book tv has provided uninterrupted coverage of the national book festival featuring hundreds of authors. book tv returns live in person to the library of congress national book festival. all day long, you will hear from and interact with guests and authors such as librarians, journalists, writers and more. library of congress national book festival live saturday, september 3 on c-span two.
>> it is your time to shine. you are invited to participate in this year's documentary competition. picture yourself as a newly elected member of congress. we ask this year's competitors, what is your top priority and why? don't be afraid to take risks with your documentary. the grand prize is $5,000. visit our website for competition rules, tips, resources, and the step-by-step guide.
IN COLLECTIONSCSPAN Television Archive Television Archive News Search Service
Uploaded by TV Archive on